Dexmedetomidine alleviates vacuolization and necrosis in tubular epithelial cells induced by aortic cross-clamping

View/ Open
Access
info:eu-repo/semantics/openAccessDate
2023Author
Ergene, ŞabanHemşinli, Doğuş
Karakişi, Sedat Ozan
Tümkaya, Levent
Mercantepe, Tolga
Yılmaz, Adnan
Metadata
Show full item recordCitation
Ergene, S., Hemsinli, D., Karakisi, S. O., Tumkaya, L., Mercantepe, T., & Yılmaz, A. (2023). Dexmedetomidine alleviates vacuolization and necrosis in tubular epithelial cells induced by aortic cross-clamping. European review for medical and pharmacological sciences, 27(8), 3396–3405. https://doi.org/10.26355/eurrev_202304_32110Abstract
OBJECTIVE: Acute kidney inju-ry (AKI) is one of the main causes of mortality in patients undergoing emergency surgery due to an abdominal aortic aneurysm. This study aimed to determine the potential nephroprotec-tive characteristics of dexmedetomidine (DMD) for the establishment of a standard therapeutic method for AKI.MATERIALS AND METHODS: Thirty Spra-que Dawley rats were allocated to 4 groups: con-trol, sham, ischemia-reperfusion, and ischemia/ reperfusion (I/R)+dexmedatomidine.RESULTS: Necrotic tubules, degenerative Bowman's capsule and vascular congestion were observed in the I/R group. In addition, there was an increase in tissue malondialdehyde (MDA), interleukin (IL)-1 and IL-6 levels in tubu-lar epithelial cells. In contrast, we observed de-creased tubular necrosis, IL-1, IL-6 and MDA lev-els in the DMD treatment group.CONCLUSIONS: DMD has a nephroprotective effect against acute kidney injury resulting from I/R, which is related to aortic occlusion used in the treatment of ruptured abdominal aortic an-eurysms.